NPC2 — NPC Intracellular Cholesterol Transporter 2

NPC2 — NPC Intracellular Cholesterol Transporter 2

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">NPC2 — NPC Intracellular Cholesterol Transporter 2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>NPC2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>NPC intracellular cholesterol transporter 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>14q11.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10577</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>607015</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000119655</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O15148</td>
</tr>
<tr>
<td class="label">Phenotype</td>
<td>Features</td>
</tr>
<tr>
<td class="label">Childhood-onset</td>
<td>Hepatosplenomegaly, neurological deterioration</td>
</tr>
<tr>
<td class="label">Adult-onset</td>
<td>Psychiatric symptoms, ataxia</td>
</tr>
<tr>
<td class="label">Infantile</td>
<td>Severe, rapid progression</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">NPC1</td>
<td>Direct handoff</td>
</tr>
<tr>
<td class="label">ApoE</td>
<td>Cholesterol binding</td>
</tr>
<tr>
<td class="label">LAMP1/2</td>
<td>Lysosomal stability</td>
</tr>
<tr>
<td class="label">GBA</td>
<td>Shared pathway</td>
</tr>
<tr>
<td class=

NPC2 — NPC Intracellular Cholesterol Transporter 2

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">NPC2 — NPC Intracellular Cholesterol Transporter 2</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>NPC2</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>NPC intracellular cholesterol transporter 2</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>14q11.2</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10577</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>607015</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000119655</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O15148</td>
</tr>
<tr>
<td class="label">Phenotype</td>
<td>Features</td>
</tr>
<tr>
<td class="label">Childhood-onset</td>
<td>Hepatosplenomegaly, neurological deterioration</td>
</tr>
<tr>
<td class="label">Adult-onset</td>
<td>Psychiatric symptoms, ataxia</td>
</tr>
<tr>
<td class="label">Infantile</td>
<td>Severe, rapid progression</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">NPC1</td>
<td>Direct handoff</td>
</tr>
<tr>
<td class="label">ApoE</td>
<td>Cholesterol binding</td>
</tr>
<tr>
<td class="label">LAMP1/2</td>
<td>Lysosomal stability</td>
</tr>
<tr>
<td class="label">GBA</td>
<td>Shared pathway</td>
</tr>
<tr>
<td class="label">Treatment</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Miglustat (Zavesca)</td>
<td>Substrate reduction therapy</td>
</tr>
<tr>
<td class="label">Arimoclomol</td>
<td>HSP90 inducer</td>
</tr>
<tr>
<td class="label">Intravenous 2-hydroxypropyl-β-cyclodextrin</td>
<td>Cholesterol extraction</td>
</tr>
<tr>
<td class="label">Therapy</td>
<td>Trial Phase</td>
</tr>
<tr>
<td class="label">VTS-101</td>
<td>Phase 1/2</td>
</tr>
<tr>
<td class="label">Cyclodextrin derivatives</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Small molecule correctors</td>
<td>Discovery</td>
</tr>
<tr>
<td class="label">Treatment</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">Miglustat (Zavesca)</td>
<td>Substrate reduction therapy</td>
</tr>
<tr>
<td class="label">Arimoclomol</td>
<td>HSP90 inducer</td>
</tr>
<tr>
<td class="label">Intravenous 2-hydroxypropyl-β-cyclodextrin</td>
<td>Cholesterol extraction</td>
</tr>
<tr>
<td class="label">Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Substantia Nigra</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Cerebral Cortex</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Striatum</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/diabetes" style="color:#ef9a9a">Diabetes</a>, <a href="/wiki/type-2-diabetes" style="color:#ef9a9a">Type 2 Diabetes</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">4 edges</a></td>
</tr>
</table>

Npc2 — Npc Intracellular Cholesterol Transporter 2 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Function

NPC2 encodes a small lysosomal cholesterol transport protein (Niemann-Pick disease, type C2). The protein is a 151-amino acid secreted glycoprotein that binds cholesterol and facilitates its transport out of the lysosome.

NPC2 works together with NPC1 to export cholesterol from late endosomes/lysosomes. Mutations in either gene cause Niemann-Pick disease type C, a fatal lysosomal storage disorder.[@vanier2020]

Gene and Protein Structure

NPC2 encodes a 151 amino acid protein:

• Signal peptide: Secretory pathway targeting
• Lysosomal targeting motif: Mannose-6-phosphate independent
• Hydrophobic pocket: Binds cholesterol/oxysterols
• Disulfide bonds: Stabilizes protein structure

Molecular Mechanisms

Lysosomal Cholesterol Export

• Cholesterol binding: Hydrophobic pocket binds cholesterol
• Handoff to NPC1: Transfers cholesterol to NPC1
• Endosomal export: Facilitates cholesterol exit from lysosomes
• Cellular distribution: Enables cholesterol to reach ER and plasma membrane

Interaction with NPC1

• NPC2 binds cholesterol in lysosomal lumen
• Transfers to N-terminal domain of NPC1
• NPC1 mediates efflux to cytosol
• Disruption causes cholesterol accumulation

Lipid Binding

• Cholesterol (primary)
• Oxysterols
• Phospholipids
• May have signaling functions

Disease Associations

Niemann-Pick Disease Type C (NPC)

Neurological symptoms:

• Cerebellar ataxia
• Dystonia
• Seizures
• Vertical supranuclear gaze palsy
• Cognitive decline/dementia
• Psychiatric manifestations

Huntington's Disease

• NPC2 expression altered in HD
• May affect mutant [huntingtin](/proteins/huntingtin-protein) clearance
• No definitive genetic association

Alzheimer's Disease

• May affect cholesterol homeostasis
• Possible link to [Aβ](/proteins/amyloid-beta) metabolism
• Requires further investigation

Brain-Specific Functions

NPC2 plays critical roles in maintaining cholesterol homeostasis in the central nervous system[munkacsi2007]:

Neuronal Cholesterol Metabolism

• Cholesterol efflux: Facilitates cholesterol export from neurons
• Myelin maintenance: Supports oligodendrocyte function
• Synaptic function: Required for synaptic vesicle trafficking
• Axonal health: Protects against demyelination

Glial Cell Functions

In [astrocytes](/entities/astrocytes) and [microglia](/entities/microglia):

• Regulates cellular cholesterol pools
• Supports lipid raft formation
• Modulates inflammatory responses

Interactions with Other Proteins

NPC2 coordinates with several proteins in lipid metabolism[@fischer2019][fischer2019]:

Therapeutic Targeting

Approved Therapies

Gene Therapy Approaches

Gene therapy represents a promising approach for NPC2 deficiency[@carstea2004][carstea2004]:

• AAV vector delivery: Direct CNS administration
• Liver-directed gene therapy: Cross-correction to brain
• mRNA delivery: Transient protein expression

Clinical Trials and Pipeline

Current Investigational Therapies

Therapeutic Implications

Approved Therapies

Experimental Approaches

• Gene therapy: AAV-NPC2 delivery
• Small molecules: Cholesterol efflux enhancers
• Enzyme replacement: Not applicable (intracellular)
• Stem cell therapy: Investigational

Animal Models

Knockout Mice

• Npc2-/- mice show:
• Progressive neurodegeneration
• Cholesterol accumulation
• Purkinje cell loss
• Short lifespan (~8-10 weeks)

Disease Models

• Transgenic mice expressing mutant NPC2:
• Phenocopy human NPC disease
• Response to therapeutic interventions

Expression Pattern

NPC2 is ubiquitously expressed:

• Highest in liver, spleen, brain
• In brain: [neurons](/entities/neurons), [astrocytes](/entities/astrocytes), [microglia](/entities/microglia)
• Lysosomal localization in all cell types

Key Publications

See Also

• [Niemann-Pick Disease Type C](/diseases/niemann-pick-disease-type-c)
• [NPC1 Gene](/proteins/npc1-protein)
• [Lysosomal Storage Disorders](/diseases/lysosomal-storage-disorders)
• [Cholesterol Metabolism](/mechanisms/brain-cholesterol-metabolism)
• [Lysosomal Function](/mechanisms/autophagy-lysosomal-pathway)
• [Astrocytes](/cell-types/astrocytes)
• [Microglia](/cell-types/microglia)

External Links

• [NCBI Gene: NPC2](https://www.ncbi.nlm.nih.gov/gene/10577)
• [UniProt: O15148](https://www.uniprot.org/uniprot/O15148)
• [Ensembl: NPC2](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119655)
• [GeneCards: NPC2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=NPC2)
• [OMIM: NPC2](https://www.omim.org/entry/607015)

Background

The study of Npc2 — Npc Intracellular Cholesterol Transporter 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

• [Allen Human Brain Atlas - NPC2 Expression](https://human.brain-map.org/microarray/search/show?search_term=NPC2)
• [Allen Cell Type Atlas](https://celltypes.brain-map.org/)
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/)

References

^[1] Millard EE, et al. The cholesterol-binding protein NPC2. J Biol Chem. 2000;275(8):5173-5180.

^[2] Xie X, et al. NPC2 deficiency accelerates neurodegeneration in mouse models. Acta Neuropathol. 2019;137(3):443-462.

^[3] Vanier MT, et al. Niemann-Pick disease type C. Nat Rev Dis Primers. 2020;6(1):8.

^[4] Platt FM, et al. NPC disease: emerging therapies. J Inherit Metab Dis. 2018;41(4):541-553.

^[5] Patterson MC, et al. Miglustat for NPC: clinical outcomes. Neurology. 2020;94(21):e2218-e2227.

Molecular Mechanisms in Detail

Cholesterol Binding and Transfer

The molecular mechanism of NPC2-mediated cholesterol transport has been elucidated through structural studies[nan2019]. The NPC2 protein contains a hydrophobic cavity that specifically binds cholesterol molecule:

• Cholesterol orientation: The steroid nucleus sits in the hydrophobic pocket with the hydrocarbon tail extending outward
• Binding affinity: KD approximately 10-100 nM for cholesterol
• Transfer mechanism: Cholesterol transfer to NPC1 occurs through a handshaking mechanism involving direct protein-protein interaction

Interaction with NPC1 Protein

The coordinated function of NPC2 and NPC1 represents a critical pathway for cholesterol egress from lysosomes:

Role in Cellular Cholesterol Homeostasis

NPC2 function impacts multiple aspects of cellular cholesterol handling:

• Cholesterol esterification: ACAT-mediated cholesterol esterification in the ER
• LDL receptor regulation: Cholesterol homeostasis affects LDL receptor expression
• Lipid raft composition: Cholesterol distribution influences membrane microdomains
• Sterol regulatory element binding proteins (SREBPs): NPC2 dysfunction affects SREBP cleavage and activation

Neurodegeneration Mechanisms

In neuronal cells, NPC2 dysfunction leads to neurodegeneration through several interconnected pathways:

• Lipid accumulation: Unesterified cholesterol and glycolipids accumulate in lysosomes
• Autophagy blockade: Lysosomal dysfunction impairs autophagic flux
• ER stress: Cholesterol accumulation in the ER triggers unfolded protein response
• Mitochondrial dysfunction: Altered cholesterol affects mitochondrial membrane composition
• Neuroinflammation: Microglial activation in response to neuronal injury

Synaptic Function Implications

NPC2 is essential for proper synaptic function:

• Synaptic vesicle cholesterol: Required for synaptic vesicle formation and function
• Presynaptic terminal: Cholesterol affects synaptophysin and synaptotagmin positioning
• Postsynaptic density: PSD-95 and receptor distribution affected by cholesterol levels
• Neurotransmitter release: Altered exocytosis dynamics

Therapeutic Approaches and Clinical Development

Substrate Reduction Therapy

Miglustat (Zavesca) represents the first FDA-approved therapy for NPC[patterson2020]:

• Mechanism: Inhibits glucosylceramide synthase
• Effect: Reduces glycolipid accumulation in lysosomes
• Clinical benefits: Slows disease progression, improves survival
• Limitations: Not curative, gastrointestinal side effects

Pharmacological Chaperones

Small molecules that stabilize mutant NPC2 protein:

• Target: Mutant protein folding and stability
• Approach: Increase functional protein levels
• Challenge: Many NPC2 mutations cause complete loss of function

Gene Therapy Strategies

Gene therapy represents a promising approach for NPC2 deficiency[carstea2004]:

• AAV vector delivery: Direct CNS administration
• Liver-directed gene therapy: Cross-correction to brain
• mRNA delivery: Transient protein expression
• CRISPR-based approaches: Gene editing for permanent correction

Combination Approaches

Rational combinations under investigation:

• Miglustat + cyclodextrin: Complementary mechanisms
• Gene therapy + pharmacological chaperones: Multiple targets
• Antioxidants + cholesterol normalization: Address oxidative stress

Research Model Systems

Cellular Models

• Fibroblasts: Patient-derived cells for diagnosis and drug screening
• Neurons: iPSC-derived neurons modeling NPC disease
• Organoids: Brain organoids for developmental studies

Animal Models

• Npc2 knockout mice: Show progressive neurodegeneration
• Npc2 conditional knockouts: Brain-specific models
• Zebrafish models: For high-throughput screening

Biomarkers and Diagnostics

Biochemical Markers

• Plasma oxysterols: Elevated 27-hydroxycholesterol
• Cholestane-3β,5α,6β-triol: Specific NPC biomarker
• Lysosphingolipids: Lyso-sphingomyelin

Imaging Biomarkers

• MRI: White matter abnormalities, cerebellar atrophy
• PET: Neuroinflammation markers
• DTI: White matter tract integrity

Summary

NPC2 (Niemann-Pick disease, type C2) is a small lysosomal protein essential for cholesterol export from late endosomes and lysosomes. Working in coordination with NPC1, NPC2 binds cholesterol in the lysosomal lumen and transfers it to NPC1 for export to the cytosol. Mutations in NPC2 cause Niemann-Pick disease type C, a fatal neurodegenerative disorder characterized by cholesterol accumulation, progressive ataxia, dementia, and early death. The protein also plays important roles in brain cholesterol homeostasis, synaptic function, and glial cell biology. Understanding NPC2 function provides insights into broader mechanisms of neurodegeneration and offers therapeutic opportunities for NPC disease and related disorders.

Allen Brain Atlas Data

Gene Expression

• Substantia nigra - Moderate expression in dopaminergic neurons
• Cerebral cortex - Moderate expression in pyramidal neurons and glia
• Hippocampus - Moderate expression in dentate gyrus and CA regions
• Basal ganglia - Moderate expression in striatal neurons

Single-Cell Expression

• Dopaminergic neurons (TH+, SLC6A3+)
• Microglia (moderate levels - lysosomal protein)
• Astrocytes (moderate levels)
• Oligodendrocytes (moderate levels)

Brain Region Expression Levels

Pathway Diagram

The following diagram shows the key molecular relationships involving NPC2 — NPC Intracellular Cholesterol Transporter 2 discovered through SciDEX knowledge graph analysis: